Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Fuller & Thaler Asset Management Inc.

Fuller & Thaler Asset Management Inc. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 55.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,731 shares of the company's stock after selling 128,668 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 0.33% of Medpace worth $33,798,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in MEDP. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its holdings in Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after buying an additional 29 shares in the last quarter. Assetmark Inc. raised its holdings in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares during the period. Proficio Capital Partners LLC lifted its position in shares of Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after buying an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. grew its position in shares of Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after purchasing an additional 30 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Price Performance

NASDAQ:MEDP traded down $0.66 during trading hours on Wednesday, reaching $305.69. 88,779 shares of the company traded hands, compared to its average volume of 340,143. The firm's 50-day moving average is $312.11 and its 200-day moving average is $331.08. The stock has a market cap of $8.79 billion, a P/E ratio of 24.20, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the company posted $3.20 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent research reports. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Truist Financial decreased their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird reduced their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Finally, Leerink Partners started coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $349.30.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.30% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.